Masahiro Morise

6PUBLICATIONS
33CO-AUTHORS
Predictive and prognostic markersSystems physiologyMolecular targetsOncology and carcinogenesis not elsewhere classifiedGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 25, 2025
Clinical benefit of PD-1/PD-L1 inhibitors for poor performance status patients with advanced non-small cell lung cancer.

Junji Koyama, Masahiro Morise, Ichidai Tanaka

|Mar 26, 2024
Real-time ultrasound-guided thoracentesis simulation using an optical see-through head-mounted display: a proof-of-concept study.

Shotaro Okachi, Toshinori Matsui, Manami Sakurai

|Feb 25, 2024
Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.

Masahiro Morise, Terufumi Kato, Shingo Matsumoto

|Aug 22, 2023
Effectiveness of crizotinib in patients with ROS1-positive non-small-cell lung cancer: real-world evidence in Japan.

Naoyuki Nogami, Atsushi Nakamura, Naoko Shiraiwa

|Dec 17, 2021
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance.

Egbert F Smit, Christophe Dooms, Jo Raskin

|Nov 18, 2021
Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE.

Akito Hata, Isamu Okamoto, Naoki Inui

Pageof 1

Frequent Collaborators

1 joint publications

Egbert F Smit

1 joint publications

Christophe Dooms

1 joint publications

Jo Raskin

1 joint publications

Ernest Nadal